BioLife Solutions FY2022 revenue $161.8M (+36% YoY); GAAP net loss $139.8M on $110.4M impairment

BIOLIFE SOLUTIONS INC

Full year 2022 revenue $161.8M, up 36% vs 2021; biopreservation media revenue grew 45%.
GAAP net loss $139.8M (includes $110.4M non-cash impairment of Stirling Ultracold intangible assets); adjusted net loss $29.3M.
Adjusted EBITDA positive at $3.6M for full year; Q4 adjusted EBITDA $1.7M.
Reaffirms 2023 revenue guidance of $188M-$202M, 16-25% growth; cell processing platform expected $89-93M (+30-35%).
Cash and short-term investments $64.1M at year-end; Silicon Valley Bank operational with existing credit facilities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BIOLIFE SOLUTIONS INC reported preliminary financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: preliminary results

Exact text from the filing

On March 16, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

BIOLIFE SOLUTIONS INC filing history →

Source: SEC EDGAR

accession 0001437749-23-006923

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.